CAR-T therapy takes on tough blood disorder in early trial
NCT ID NCT07091370
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new CAR-T cell therapy called inaticabtagene autoleucel for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. The study will enroll 12 adults and primarily check for safety and the right dose. It's a first step to see if this immune-cell therapy can help control this rare blood condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inaticabtagene autoleucel (a CAR-T cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with severe autoimmune hemolytic anemia who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, not effectiveness. CAR-T therapies can cause serious side effects like cytokine release syndrome, and it may not work for this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Engineered immune cells take aim at stubborn blood disorder
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New study aims to unlock the secrets of Children's rare blood diseases
- Experimental CAR-T therapy takes on stubborn blood disorder